PURPOSE: Specific recommendations on screening modalities for paraganglioma (PGL) and phaeochromocytoma (PCC) in asymptomatic SDHx mutation carriers (relatives) are still lacking. We evaluated the added value of (18)F-FDG PET/CT in comparison with morphological imaging at initial diagnosis and 1 year of follow-up in this population. METHODS: The study included 30 consecutive relatives with a proven SDHx mutation who were investigated by (18)F-FDG PET/CT, gadolinium-enhanced magnetic resonance angiography of the head and neck, thoracic/abdominal/pelvic (TAP) contrast-enhanced CT and/or TAP MRI. (123)I-MIBG scintigraphy was performed in 20 subjects and somatostatin receptor scintigraphy (SRS) in 20 subjects. The gold standard was based on pathology or a composite endpoint as defined by any other positive imaging method and persistent tumour on follow-up. Images were considered as false-positive when the lesions were not detected by another imaging method or not confirmed at 1 year. RESULTS: At initial work-up, an imaging abnormality was found in eight subjects (27%). The final diagnosis was true-positive in five subjects (two with abdominal PGL, one with PCC and two with neck PGL) and false-positives in the other three subjects (detected with (18)F-FDG PET/CT in two and TAP MRI in one). At 1 year, an imaging abnormality was found in three subjects of which one was an 8-mm carotid body PGL in a patient with SDHD mutaion and two were considered false-positive. The tumour detection rate was 100% for (18)F-FDG PET/CT and conventional imaging, 80% for SRS and 60% for (123)I-MIBG scintigraphy. Overall, disease was detected in 4% of the subjects at the 1-year follow-up. CONCLUSION: (18)F-FDG PET/CT demonstrated excellent sensitivity but intermediate specificity justifying combined modality imaging in these patients. Given the slow progression of the disease, if (18)F-FDG PET/CT and MRI are normal at baseline, the second imaging work-up should be delayed and an examination that does not expose the patient to radiation should be used.
PURPOSE: Specific recommendations on screening modalities for paraganglioma (PGL) and phaeochromocytoma (PCC) in asymptomatic SDHx mutation carriers (relatives) are still lacking. We evaluated the added value of (18)F-FDG PET/CT in comparison with morphological imaging at initial diagnosis and 1 year of follow-up in this population. METHODS: The study included 30 consecutive relatives with a proven SDHx mutation who were investigated by (18)F-FDG PET/CT, gadolinium-enhanced magnetic resonance angiography of the head and neck, thoracic/abdominal/pelvic (TAP) contrast-enhanced CT and/or TAP MRI. (123)I-MIBG scintigraphy was performed in 20 subjects and somatostatin receptor scintigraphy (SRS) in 20 subjects. The gold standard was based on pathology or a composite endpoint as defined by any other positive imaging method and persistent tumour on follow-up. Images were considered as false-positive when the lesions were not detected by another imaging method or not confirmed at 1 year. RESULTS: At initial work-up, an imaging abnormality was found in eight subjects (27%). The final diagnosis was true-positive in five subjects (two with abdominal PGL, one with PCC and two with neck PGL) and false-positives in the other three subjects (detected with (18)F-FDG PET/CT in two and TAP MRI in one). At 1 year, an imaging abnormality was found in three subjects of which one was an 8-mm carotid body PGL in a patient with SDHD mutaion and two were considered false-positive. The tumour detection rate was 100% for (18)F-FDG PET/CT and conventional imaging, 80% for SRS and 60% for (123)I-MIBG scintigraphy. Overall, disease was detected in 4% of the subjects at the 1-year follow-up. CONCLUSION: (18)F-FDG PET/CT demonstrated excellent sensitivity but intermediate specificity justifying combined modality imaging in these patients. Given the slow progression of the disease, if (18)F-FDG PET/CT and MRI are normal at baseline, the second imaging work-up should be delayed and an examination that does not expose the patient to radiation should be used.
Authors: Kathryn S King; Clara C Chen; Dimitrios K Alexopoulos; Millie A Whatley; James C Reynolds; Nicholas Patronas; Alexander Ling; Karen T Adams; Paraskevi Xekouki; Howard Lando; Constantine A Stratakis; Karel Pacak Journal: J Clin Endocrinol Metab Date: 2011-07-13 Impact factor: 5.958
Authors: Diana E Benn; Anne-Paule Gimenez-Roqueplo; Jennifer R Reilly; Jérôme Bertherat; John Burgess; Karen Byth; Michael Croxson; Patricia L M Dahia; Marianne Elston; Oliver Gimm; David Henley; Philippe Herman; Victoria Murday; Patricia Niccoli-Sire; Janice L Pasieka; Vincent Rohmer; Kathy Tucker; Xavier Jeunemaitre; Deborah J Marsh; Pierre-François Plouin; Bruce G Robinson Journal: J Clin Endocrinol Metab Date: 2005-11-29 Impact factor: 5.958
Authors: Henri J L M Timmers; Clara C Chen; Jorge A Carrasquillo; Millie Whatley; Alexander Ling; Graeme Eisenhofer; Kathryn S King; Jyotsna U Rao; Robert A Wesley; Karen T Adams; Karel Pacak Journal: J Natl Cancer Inst Date: 2012-04-18 Impact factor: 13.506
Authors: Giorgio Treglia; Fabrizio Cocciolillo; Chiara de Waure; Francesco Di Nardo; Maria Rosaria Gualano; Paola Castaldi; Vittoria Rufini; Alessandro Giordano Journal: Eur J Nucl Med Mol Imaging Date: 2012-02-23 Impact factor: 9.236
Authors: Kory W Jasperson; Wendy Kohlmann; Amanda Gammon; Heidi Slack; Luke Buchmann; Jason Hunt; Anne C Kirchhoff; Henry Baskin; Akram Shaaban; Joshua D Schiffman Journal: Fam Cancer Date: 2014-06 Impact factor: 2.375
Authors: David Taïeb; Rodney J Hicks; Elif Hindié; Benjamin A Guillet; Anca Avram; Pietro Ghedini; Henri J Timmers; Aaron T Scott; Saeed Elojeimy; Domenico Rubello; Irène J Virgolini; Stefano Fanti; Sona Balogova; Neeta Pandit-Taskar; Karel Pacak Journal: Eur J Nucl Med Mol Imaging Date: 2019-06-29 Impact factor: 9.236
Authors: Berdine L Heesterman; Lisa M H de Pont; Andel Gl van der Mey; Jean-Pierre Bayley; Eleonora Pm Corssmit; Frederik J Hes; Berit M Verbist; Peter Paul G van Benthem; Jeroen C Jansen Journal: Eur J Hum Genet Date: 2018-05-18 Impact factor: 4.246
Authors: Daniel Kaemmerer; Jörg Sänger; Ruza Arsenic; Jan G D'Haese; Jens Neumann; Annette Schmitt-Graeff; Ralph Markus Wirtz; Stefan Schulz; Amelie Lupp Journal: Oncotarget Date: 2017-09-23
Authors: Katrina A Andrews; David B Ascher; Douglas Eduardo Valente Pires; Daniel R Barnes; Lindsey Vialard; Ruth T Casey; Nicola Bradshaw; Julian Adlard; Simon Aylwin; Paul Brennan; Carole Brewer; Trevor Cole; Jackie A Cook; Rosemarie Davidson; Alan Donaldson; Alan Fryer; Lynn Greenhalgh; Shirley V Hodgson; Richard Irving; Fiona Lalloo; Michelle McConachie; Vivienne P M McConnell; Patrick J Morrison; Victoria Murday; Soo-Mi Park; Helen L Simpson; Katie Snape; Susan Stewart; Susan E Tomkins; Yvonne Wallis; Louise Izatt; David Goudie; Robert S Lindsay; Colin G Perry; Emma R Woodward; Antonis C Antoniou; Eamonn R Maher Journal: J Med Genet Date: 2018-01-31 Impact factor: 6.318